Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 11/20 | 0.44 |
| ▸ | CA9 | Q16790 | 11/20 | 0.44 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | CA1 | P00915 | 6/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.41 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14973056 | 0.95 | CA9 (0.47) | S1PR1POLBCA2CA9CA12 | |
| SCHEMBL14972979 | 0.91 | S1PR1 (0.45) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL14972959 | 0.91 | POLB (0.45) | S1PR1POLBSMPD1FFAR1CHUK | |
| SCHEMBL14973080 | 0.90 | CA2 (0.45) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL14973104 | 0.90 | CA9 (0.46) | S1PR1POLBCA2CA9CA12 | |
| SCHEMBL14972950 | 0.90 | S1PR1 (0.46) | S1PR1POLBCA2CA9CA12 | |
| SCHEMBL14973011 | 0.89 | S1PR1 (0.46) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL14973246 | 0.89 | CA2 (0.49) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL14973326 | 0.88 | S1PR1 (0.46) | S1PR1CA2CA9CA12CA1 | |
| SCHEMBL14973249 | 0.87 | CXCR1 (0.46) | S1PR1POLBSMPD1FFAR1CHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137865-A1 | HETEROARYL-PYRAZOLE DERIVATIVE | GRIN2C, GRIN2B, GRIN3A | S1PR1 2686/4885POLB 3540/4885CA2 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.